International Edition
Latest News
Health

COVID-19 mRNA Vaccines Boost Survival in Cancer Patients on Immunotherapy

Patients with advanced melanoma or lung cancer who received COVID-19 mRNA vaccines alongside immune checkpoint inhibitor therapy experienced substantially better survival outcomes than those receiving immunotherapy alone, The Conversation reported. The findings indicate that viral vaccination could make…

COVID-19 mRNA Vaccines Boost Survival in Cancer Patients on Immunotherapy

Patients with advanced melanoma or lung cancer who received COVID-19 mRNA vaccines alongside immune checkpoint inhibitor therapy experienced substantially better survival outcomes than those receiving immunotherapy alone, The Conversation reported.

The findings indicate that viral vaccination could make existing cancer treatments more effective, although researchers note that further investigation is necessary. Modern immunotherapy began in 2011 with the approval of the first immune checkpoint inhibitor drug, ipilimumab, followed in 2014 by pembrolizumab for metastatic melanoma.

Immune checkpoint inhibitor therapy uses proteins called PD-1 and CTLA-4, which act as inhibitory receptors on the surface of T cells. These proteins function as biological brakes to stop T cells from attacking healthy tissue. Checkpoint inhibitor drugs temporarily release those brakes, allowing rare cancer-fighting T cells to multiply and destroy cancer cells throughout the body.

Before checkpoint inhibitor therapy, patients with late-stage metastatic melanoma or lung cancer faced poor survival odds. However, these treatments currently work for only about 30% of patients.

'Amazing progress' in lung cancer: Immunotherapy extends survival as mRNA vaccines offer hope — FRANCE 24 English

Viral Versus Tumor Immunity

Fighting cancer relies on rare T cells that spot abnormal proteins known as cancer neoantigens, which are created when cells grow abnormally. While these T cells use the same detection machinery to find cancer as they do virus-infected cells, the immune response is far less effective against tumors than it is against viruses.

Viral immunity benefits from an innate sensing system that detects molecular patterns unique to pathogens. Pattern recognition receptors sense these markers and react quickly to boost the immune response.

Many viruses carry RNA with a distinct structure that the immune system easily flags as a foreign threat. In cancer, tumors look too similar to healthy cells, lacking an equivalent foreign pattern to trigger anti-cancer T cells.

Study suggests link between MRNA COVID vaccine and longer lives for cancer patients — KTVN 2 News Nevada

mRNA Vaccine Mechanisms

After observing that vaccinated cancer patients seemed to respond better to checkpoint inhibitor drugs, researchers conducted a retrospective study of melanoma and lung cancer patients. The data showed that patients who also received a COVID mRNA vaccine had nearly double the three-year survival rate.

The researchers discovered that the vaccine’s mRNA activates an immune sensor called MDA5. This triggers a strong antiviral response that pre-sensitizes the immune system and makes checkpoint inhibitor drugs more effective.

If confirmed in clinical trials, this approach could improve outcomes across a wider range of cancers. The discovery also opens new avenues of research into how immunotherapy might be optimized with other innate pattern recognition boosters.

Personalized Cancer Vaccines

Another promising development involves the clinical trial success of personalized mRNA cancer vaccines. These trials encode patient-specific neoantigens as mRNA and package them inside lipid nanoparticles before and during checkpoint inhibitor therapy.

One approach yielded encouraging results against pancreatic cancer, which is considered largely unresponsive to checkpoint inhibitor treatment alone. Personalized vaccines must be tailored for each patient, making them complex and expensive to produce.

The discovery of the mRNA boosting effect could help researchers develop simpler vaccines without the complexity of personalized neoantigens. Because the current findings stem from retrospective patient data, clinical trials are required to confirm whether vaccination directly caused the improved survival.

Common Cancer Vaccine Questions

How do lipid nanoparticles assist mRNA vaccines? Lipid nanoparticles are microscopic fat droplets that protect fragile mRNA and shuttle it into immune cells.

What historical treatment predated modern immunotherapy? New York surgeon William B. Coley injected crude bacterial extracts into patients with massive, inoperable tumors in a treatment that dates back more than 100 years.

Which specific receptors are targeted by checkpoint inhibitors? Checkpoint inhibitor therapy specifically targets PD-1 and CTLA-4 proteins acting as inhibitory receptors on T lymphocytes.

About the author: Health Desk

Health Desk at Archynewsy.